

Supporting Information

Experimental and Mechanistic Insights of Copper(II)-dioxygen Catalyzed Oxidative *N*-dealkylation of *N*-(2-pyridylmethyl)phenylamine and Its Derivatives

Yang Wang, Haixiong Liu, Xiaofeng Zhang, Zilong Zhang and Deguang Huang*

State Key Laboratory of Structural Chemistry, Fujian Institute of Research on the Structure of
Matter, Chinese Academy of Sciences, Fuzhou, Fujian 350002, China



*To whom correspondence should be addressed. E-mail: dhuang@fjirsm.ac.cn

1. Crystallographic data and X-ray structures of compounds.....	S2
2. General information.....	S3
3. Experimental procedure for inorganic compounds	S3-S5
4. General experimental procedure A-E for organic synthesis	S5-S17
5. References.....	S17
6. NMR and Mass spectra.....	S18-S54

Table S1. Crystallographic Data^a for Compounds **1a-1b** and **1d-1f**.

compounds	[1a]	[1b]	[1d]	[1e]	[1f]
formula	C ₂₀ H ₁₉ CuF ₆ N ₃ O ₇ S ₂	C ₂₅ H ₂₁ CuF ₃ N ₄ O ₅ S	C ₂₈ H ₃₀ CuF ₆ N ₆ O ₆ S ₂	C ₂₇ H ₂₇ CuF ₆ N ₅ O ₆ S ₂	C ₃₃ H ₃₁ CuF ₆ N ₅ O ₆ S ₂
<i>M</i>	655.04	610.06	788.24	759.20	835.29
crystal system	orthorhombic	monoclinic	triclinic	triclinic	triclinic
space group	<i>P</i> 2 ₁ 2 ₁ 2 ₁	<i>P</i> 2 ₁ / <i>n</i>	<i>P</i> -1	<i>P</i> -1	<i>P</i> -1
<i>a</i> , Å	8.68300(16)	13.4993(3)	10.1705(4)	8.9816(4)	10.0986(12)
<i>b</i> , Å	10.2079(2)	8.9437(2)	12.0872(4)	10.9461(4)	13.5819(14)
<i>c</i> , Å	27.0713(6)	20.9454(5)	14.4087(6)	16.4679(9)	15.2704(16)
α , deg	90	90	93.643(3)	81.550(4)	68.475(10)
β , deg	90	100.521(2)	110.216(4)	77.177(4)	72.790(10)
γ , deg	90	90	95.074(3)	87.632(3)	73.322(10)
<i>V</i> , Å ³	2399.47(8)	2486.30(11)	1647.25(11)	1561.44(13)	1823.2(3)
<i>Z</i>	4	4	2	2	2
μ , mm ⁻¹	3.810	2.640	2.889	3.014	2.641
independent data	3815	4745	6209	5951	6796
refined parameters	358	352	442	427	591
<i>R</i> ₁ ^b , <i>wR</i> ₂ ^c (<i>I</i> > 2 σ (<i>I</i>))	0.0232, 0.0589	0.0477, 0.1274	0.0581, 0.1854	0.0433, 0.1125	0.1146, 0.3084
<i>R</i> ₁ , <i>wR</i> ₂ (all data)	0.0251, 0.0602	0.0609, 0.1360	0.0629, 0.1872	0.0521, 0.1168	0.1586, 0.3220

^a*T* = 100(2) K, Cu K α radiation (λ = 1.54184 Å). ^b*R*₁ = $\sum||F_o| - |F_c|| / \sum|F_o|$. ^c*wR*₂ = $\{\sum[w(F_o^2 - F_c^2)^2 / (F_o^2)]\}^{1/2}$.


**Figure S1** Crystal structures of **1c** (a) (Note: CIF file was NOT reported due to poor data; Structure was shown for comparison) and **1d** (b) (CCDC 1561119) showing 50% probability ellipsoid.**Figure S2** Crystal structures of complexes **1e** (a) (CCDC 1560850) and **1f** (b) (CCDC 1560839) showing 50% probability ellipsoid. These two structures are presented here for representation of the structure of {Cu^{II}(L_N)[(PyCH₂)NH(PhCH₃)]} moiety from the point of analogues.

1. General Information

All chemicals were purchased from commercial suppliers and used without further purification. Solvent DMF and CH₃CN were dried over CaH₂ and stored in the presence of activated molecular sieve. Flash chromatography was performed on silica gel (200-300 mesh). The single crystal data of compounds were collected by a Cu-K α rotating anode source at 100 K, using a Supernova diffractometer with the ω -scan method. ESI-MS were obtained using a Bruker Impact II quadrupole time-of-flight mass spectrometer. ¹H NMR spectra were recorded on Bruker Avance III (400 MHz) and chemical shifts are expressed in δ ppm values with reference to tetramethylsilane (TMS) as internal standard. NMR multiplicities are abbreviated as follows: s = singlet, d = doublet, m = multiplet. Coupling constants (J) are expressed in Hz. Product yields refer to isolated yields after column chromatography. All commercial reagents were purchased from Alfa, Sigma Aldrich, Energy Chemical or TCI.


2. Experimental procedure for inorganic compounds

(1) [Cu^{II}(L_N)(H₂O)(OTf)](OTf) (1a)



To a solution of Cu(OTf)₂ (18 mg, 0.05 mmol) and H₂O (0.1 mL) in MeCN (3 mL) was added a solution of *N,N*-bis(pyridin-2-ylmethyl)aniline (13.7 mg, 0.05 mmol) in MeCN (2 mL). The mixture was stirred for 5h under nitrogen atmosphere and concentrated under reduced pressure. The residue was washed with Et₂O and THF, dissolved in MeCN and diffused with Et₂O to yield the product as some green crystals (26.1mg, 80%). Anal. Calcd. (%) for C₂₀H₁₉CuF₆N₃O₇S₂: C, 36.67; H, 2.92; N, 6.41. Found (%) C, 36.45; H, 3.19; 6.73.

(2) {[Cu^{II}(L_N)(PyCOO)](OTf)}_n (1b)




Method A: To a solution of compound **1a** (32.6 mg, 0.05 mmol) in MeCN/H₂O (5/0.1 mL) was added *N*-(pyridin-2-ylmethyl)aniline (9.2 mg, 0.05 mmol) and Et₃N (0.1 mL). The mixture was stirred overnight under O₂ atmosphere for 24 h and concentrated under reduced pressure. The residue was washed with Et₂O, dissolved in THF and diffused with Et₂O to yield the product as green crystals (16 mg, 53%). Anal. Calcd. (%) for C₂₅H₂₁CuF₃N₄O₅S: C, 49.22; H, 3.47; N, 9.18. Found (%) C, 48.86; H, 3.09; N, 9.87. ESI-MS (MeCN): *m/z* 460.3 for [Cu(DPA-Ph)(PyCOO)]⁺.

Method B: A mixture of *N,N*-bis(pyridin-2-ylmethyl)aniline (13.7 mg, 0.05 mmol) and Cu(OTf)₂ (18 mg, 0.05 mmol) were stirred in MeCN/H₂O (5/0.1 mL) for 1 h before *N*-(pyridin-2-ylmethyl)-


aniline (9.2 mg, 0.05 mmol) and Et₃N (0.1 mL) were added. The mixture was stirred in O₂ atmosphere for 24 h and solvent removed in vacuo. The residue was washed with Et₂O, dissolved in THF and diffused with Et₂O to afford the product as green crystals (15 mg, 50%).

(3) [Cu^{II}(DPA)₂](CF₃SO₃)₂ (1c)




To a solution of compound **1a** (32.6mg, 0.05mmol) in MeCN (5 mL) was added di-(2-picolyl)amine (DPA) (10 mg, 0.05 mmol) and Et₃N (0.1 mL). The mixture was stirred overnight under O₂ atmosphere for 24h and concentrated under reduced pressure. The residue was washed with Et₂O and THF, dissolved in CH₃CN and diffused with Et₂O to yield the product as blue crystals (7.4 mg, 32%). Anal. Calcd. (%) for C₃₀H₃₄CuF₆N₆O₆S₂: C, 44.14; H, 4.20; N, 10.30. Found (%) C, 43.98; H, 4.51; 10.02

(4) [Cu^{II}(DPA-CH₃)₂](CF₃SO₃)₂ (1d)




To a solution of compound **1a** (25 mg, 0.05 mmol) in MeCN (5 mL) was added N-methyl-N,N-di(2-pyridylmethyl)amine (DPA-CH₃) (11 mg, 0.05 mmol) and Et₃N (0.1 mL). The mixture was stirred overnight under O₂ atmosphere for 24h and concentrated under reduced pressure. The residue was washed with Et₂O and THF, dissolved in CH₃CN and diffused with Et₂O to yield the product as blue crystals (6.1 mg, 25%). Anal. Calcd. (%) for C₂₈H₃₀CuF₆N₆O₆S₂: C, 42.66; H, 3.84; N, 10.66. Found (%) C, 43.23; H, 3.21; 10.12.

(5) [Cu^{II}(L_N)(PyCH₂NHCH₃)(CF₃SO₃)](CF₃SO₃) (1e)




To a solution of compound **1a** (32.6 mg, 0.05 mmol) in MeCN (5 mL) was added N-methyl-1-(pyridin-2-yl)methanamine (6.2 mg, 0.05 mmol) and Et₃N (0.1 mL). The mixture was stirred overnight under O₂ atmosphere for 24h and concentrated under reduced pressure. The residue was washed with Et₂O, dissolved in THF and diffused with Et₂O to yield the product as blue crystals (28.5 mg, 75%). Anal. Calcd. (%) for C₂₇H₂₇CuF₆N₅O₆S₂: C, 42.71; H, 3.58; N, 9.22. Found (%) C, 42.36; H, 3.12; 9.79.

(6) [Cu^{II}(L_N)(PyCH₂NHCH₂Ph)(CF₃SO₃)](CF₃SO₃) (1f)



To a solution of compound **1a** (32.6 mg, 0.05 mmol) in MeCN (5 mL) was added *N*-benzyl-1-(pyridin-2-yl)methanamine (9.9 mg, 0.05 mmol) and Et₃N (0.1 mL). The mixture was stirred overnight under O₂ atmosphere for 24h and concentrated under reduced pressure. The residue was washed with Et₂O, dissolved in THF and diffused with Et₂O to yield the product as blue crystals (22.1 mg, 53%). Anal. Calcd. (%) for C₃₃H₃₁CuF₆N₅O₆S₂: C, 47.45; H, 3.74; N, 8.38. Found (%) C, 47.94; H, 4.01; 8.12.

(7) PyCOOH




The compound **1b** (0.1 mmol) was stirred in concentrated HCl (37%, 1 mL) for 2 hours and the resultant solution was extracted with CH₂Cl₂ (3×20 mL). The combined organic layer was washed with water (3×10 mL) and dried over anhydrous Na₂SO₄ over night. The white solid was filtered off and the solvent was removed in vacuo. The residue was washed with Et₂O to give product as some white solid (6.4 mg, 61%).

3. General experimental procedure A-E for organic synthesis

General Experimental Procedure A


Cu(OTf)₂ (3.6 mg, 0.01 mmol), *N,N*-bis(pyridin-2-ylmethyl)phenylamine (L_N) (4.1 mg, 0.015 mmol), *t*-BuOK (22.4 mg, 0.2 mmol), *N*-(pyridin-2-ylmethyl)aniline derivatives (0.1 mmol) were mixed in dried DMF (1 mL) in a 35 mL Teflon screw-cap sealed tube. The tube was charged with O₂ (1 atm) and the mixture was vigorously stirred at RT for 24 h. After reaction was completed, the reaction mixture was diluted with dichloromethane (20 mL), filtered through a pad of silica gel and concentrated under reduced pressure. The crude product was purified on a silica gel column.

(8) *N*-phenylpicolinamide (2a)¹




Following the general experimental procedure A presented above, using *N*-(pyridin-2-ylmethyl)aniline (18.4 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as yellow solid (75% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.20 – 9.91 (m, 1H), 8.64 (d, *J* = 4.7 Hz, 1H), 8.33 (d, *J* = 7.8 Hz, 1H), 7.93 (td, *J* = 7.7, 1.7 Hz, 1H), 7.85 – 7.78 (m, 2H), 7.56 – 7.46 (m, 1H), 7.42 (dd, *J* = 10.8, 5.1 Hz, 2H), 7.18 (t, *J* = 7.4 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 162.01, 149.82, 147.99, 137.76, 137.71, 129.11, 126.48, 124.34, 122.43, 119.70. HRMS *m/z* (ESI) [M + Na⁺]: 221.0685.

(9) N-(p-tolyl)picolinamide (2b)²




Following the general experimental procedure A presented above, using *4-methyl-N-(pyridin-2-ylmethyl)aniline* (19.8 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (92% yield); ¹H NMR (400 MHz, CDCl₃): δ 9.99 (s, 1H), 8.63 (d, *J* = 4.7 Hz, 1H), 8.40 – 8.26 (m, 1H), 7.98 – 7.86 (m, 1H), 7.71 (t, *J* = 8.8 Hz, 2H), 7.55 – 7.45 (m, 1H), 7.20 (t, *J* = 10.0 Hz, 2H), 2.37 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 161.87, 149.95, 147.95, 137.66, 135.23, 133.93, 129.60, 126.36, 122.37, 119.68, 20.95.

(10) N-(m-tolyl)picolinamide (2c)²




Following the general experimental procedure A presented above, using *3-methyl-N-(pyridin-2-ylmethyl)aniline* (19.8 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a colorless oil (68% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.07 (d, *J* = 44.7 Hz, 1H), 8.64 (ddd, *J* = 4.8, 1.6, 0.9 Hz, 1H), 8.32 (dt, *J* = 7.8, 1.0 Hz, 1H), 7.93 (td, *J* = 7.7, 1.7 Hz, 1H), 7.68 (d, *J* = 4.7 Hz, 1H), 7.60 (d, *J* = 8.0 Hz, 1H), 7.50 (ddd, *J* = 7.6, 4.8, 1.2 Hz, 1H), 7.29 (q, *J* = 3.1 Hz, 1H), 6.99 (d, *J* = 7.6 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 161.96, 149.90, 147.96, 139.01, 137.69, 137.66, 128.92, 126.42, 125.16, 122.39, 120.34, 116.80, 21.55.

(11) N-(o-tolyl)picolinamide (2d)³




Following the general experimental procedure A presented above, using *2-methyl-N-(pyridin-2-ylmethyl)aniline* (19.8 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a colorless oil (51% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.12 (s, 1H), 8.65 (dd, *J* = 5.7, 4.9 Hz, 1H), 8.32 (dd, *J* = 13.3, 7.7 Hz, 2H), 7.94 (tdd, *J* = 5.4, 3.9, 1.8 Hz, 1H), 7.55 – 7.50 (m, 1H), 7.34 – 7.29 (m, 1H), 7.26 (d, *J* = 7.4 Hz, 1H), 7.11 (td, *J* = 7.5, 1.0 Hz, 1H), 2.45 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 161.92, 150.16, 148.10, 137.67, 130.42, 128.04, 126.91, 126.41, 124.58, 122.41, 121.33, 119.69, 17.76.

(12) N-(2, 6-dimethylphenyl)picolinamide (2e)⁴




Following the general experimental procedure A presented above, using 2,6-dimethyl- N-(pyridin-2-ylmethyl)aniline (21.2 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (38% yield); ¹H NMR (400 MHz, CDCl₃): δ 9.51 (s, 1H), 8.66 (ddd, *J* = 4.8, 1.6, 0.9 Hz, 1H), 8.33 (dt, *J* = 7.8, 1.0 Hz, 1H), 7.93 (td, *J* = 7.7, 1.7 Hz, 1H), 7.52 (ddd, *J* = 7.6, 4.8, 1.2 Hz, 1H), 7.18 – 7.13 (m, 3H), 2.33 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 161.92, 150.16, 148.10, 137.67, 130.42, 128.04, 126.91, 126.41, 124.58, 122.41, 121.33, 119.69, 17.76.

(13) N-(4-ethylphenyl)picolinamide (2f)




Following the general experimental procedure A presented above, using 4-ethyl-N-(pyridin-2-ylmethyl)aniline (21.2 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a colorless oil (70% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.00 (s, 1H), 8.64 (ddd, *J* = 4.8, 1.6, 0.9 Hz, 1H), 8.32 (dt, *J* = 7.9, 1.0 Hz, 1H), 7.93 (td, *J* = 7.7, 1.7 Hz, 1H), 7.77 – 7.68 (m, 2H), 7.56 – 7.45 (m, 1H), 7.23 (t, *J* = 9.6 Hz, 2H), 2.67 (q, *J* = 7.6 Hz, 2H), 1.30 – 1.26 (m, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 161.92, 150.16, 148.10, 137.67, 130.42, 128.04, 126.91, 126.41, 124.58, 122.41, 121.33, 119.69, 17.76. HRMS *m/z* (ESI) [*M* + Na⁺]: 249.0999.

(14) N-(4-methoxyphenyl)picolinamide (2g)¹



Following the general experimental procedure A presented above, using 4-methoxy-N-(pyridin-2-ylmethyl)aniline (21.4 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (82% yield); ¹H NMR (400 MHz, CDCl₃): δ 9.89 (d, *J* = 45.7 Hz, 1H), 8.63 (ddd, *J* = 4.8, 1.6, 0.9 Hz, 1H), 8.31 (dt, *J* = 7.9, 1.0 Hz, 1H), 7.92 (td, *J* = 7.7, 1.7 Hz, 1H), 7.81 – 7.67 (m, 2H), 7.49 (ddd, *J* = 7.6, 4.8, 1.2 Hz, 1H), 7.03 – 6.92 (m, 2H), 3.84 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 161.92, 150.16, 148.10, 137.67, 130.42, 128.04, 126.91, 126.41, 124.58, 122.41, 121.33, 119.69, 17.76.


(15) N-(4-iodophenyl)picolinamide (2h)¹



Following the general experimental procedure A presented above, using 4-iodo-N-(pyridin-2-ylmethyl)aniline (31 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (80% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.11 (d, *J* = 44.9 Hz, 1H), 8.71 – 8.58 (m, 1H), 8.32 (t, *J* = 8.7 Hz, 1H), 7.94 (td,


$J = 7.7, 1.7$ Hz, 1H), 7.76 – 7.65 (m, 2H), 7.65 – 7.57 (m, 2H), 7.52 (ddd, $J = 7.6, 4.8, 1.2$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3): δ 162.06, 149.50, 148.02, 138.02, 137.79, 137.53, 126.66, 122.47, 121.53, 87.50.

(16) N-(4-(trifluoromethyl)phenyl)picolinamide (2i)²




Following the general experimental procedure A presented above, using N-(pyridin-2-ylmethyl) 4-(trifluoromethyl)aniline (25.2 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (68% yield); ^1H NMR (400 MHz, CDCl_3): δ 10.23 (s, 1H), 8.66 (d, $J = 4.7$ Hz, 1H), 8.34 (d, $J = 7.8$ Hz, 1H), 8.01 – 7.89 (m, 3H), 7.67 (d, $J = 8.6$ Hz, 2H), 7.55 (ddd, $J = 7.5, 4.8, 1.1$ Hz, 1H). ^{13}C NMR (101 MHz, CDCl_3): δ 162.30, 149.28, 148.07, 140.75, 137.87, 126.85, 126.40, 126.36, 122.60, 119.34, 100.00.

(17) N-(4-benzoylphenyl)picolinamide (2j)




Following the general experimental procedure A presented above, using phenyl-(4-((pyridin-2-ylmethyl)amino)phenyl)methanone (28.2 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (72% yield); ^1H NMR (400 MHz, CDCl_3): δ 10.29 (s, 1H), 8.67 (ddd, $J = 4.8, 1.6, 0.9$ Hz, 1H), 8.34 (dt, $J = 7.8, 1.0$ Hz, 1H), 8.06 – 7.77 (m, 7H), 7.68 – 7.47 (m, 4H). ^{13}C NMR (101 MHz, CDCl_3): δ 195.67, 162.31, 149.32, 148.09, 141.62, 137.93, 137.88, 133.10, 132.20, 131.76, 129.91, 128.29, 126.86, 122.61, 118.88. HRMS m/z (ESI) $[\text{M} + \text{H}^+]$: 303.1128.

(18) 3-methyl-N-(p-tolyl)-4-(2,2,2-trifluoroethoxy)picolinamide (2k)




Following the general experimental procedure A presented above, using 4-methyl-N-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)aniline (31 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (70% yield); ^1H NMR (400 MHz, CDCl_3): δ 10.12 (s, 1H), 8.40 (d, $J = 5.4$ Hz, 1H), 7.66 (t, $J = 10.2$ Hz, 2H), 7.20 (d, $J = 8.2$ Hz, 2H), 6.86 (d, $J = 5.5$ Hz, 1H), 4.46 (q, $J = 7.8$ Hz, 2H), 2.75 (s, 3H), 2.36 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 161.92, 150.16, 148.10, 137.67, 130.42, 128.04, 126.91, 126.41, 124.58, 122.41, 121.33, 119.69, 17.76. HRMS m/z (ESI) $[\text{M} + \text{Na}^+]$: 347.0978.

(19) 4-chloro-N-phenylpicolinamide (2l)¹




Following the general experimental procedure A presented above, using *N*-((4-chloropyridin-2-yl)-methyl)aniline (22 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (77% yield); ¹H NMR (400 MHz, CDCl₃): δ 9.94 (s, 1H), 8.54 (d, *J* = 5.2 Hz, 1H), 8.33 (d, *J* = 1.9 Hz, 1H), 7.79 (dd, *J* = 8.5, 1.0 Hz, 2H), 7.54 – 7.48 (m, 1H), 7.47 – 7.39 (m, 2H), 7.25 – 7.14 (m, 1H). ¹³C NMR (101 MHz, CDCl₃): δ 160.79, 151.34, 148.88, 146.31, 137.43, 129.16, 126.64, 124.64, 123.09, 119.77.

(20) 4-(3-methoxypropoxy)-3-methyl-N-(p-tolyl)picolinamide (2m)



Following the general experimental procedure A presented above, using *N*-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)-4-methylaniline (30 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a white solid (61% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.19 (s, 1H), 8.33 (dd, *J* = 5.3, 1.9 Hz, 1H), 7.65 (d, *J* = 6.4 Hz, 2H), 7.19 (d, *J* = 6.9 Hz, 2H), 6.90 (dd, *J* = 5.3, 2.0 Hz, 1H), 4.17 (dd, *J* = 6.1, 4.0 Hz, 2H), 3.62 (td, *J* = 5.9, 2.2 Hz, 2H), 3.39 (d, *J* = 2.5 Hz, 3H), 2.70 (d, *J* = 2.1 Hz, 3H), 2.36 (d, *J* = 1.3 Hz, 3H), 2.16 (ddd, *J* = 9.8, 8.2, 5.9 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 164.93, 163.96, 147.74, 146.26, 135.65, 133.51, 129.47, 125.64, 119.67, 108.02, 77.35, 77.03, 76.71, 68.79, 65.39, 58.82, 29.33, 20.93, 11.01. HRMS *m/z* (ESI) [M + H⁺]: 315.1705.

(21) 4-methoxy-3,5-dimethyl-N-(p-tolyl)picolinamide (2n)




Following the general experimental procedure A presented above, using *N*-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-4-methylaniline (25.6 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (46% yield); ¹H NMR (400 MHz, CDCl₃): δ 10.11 (s, 1H), 8.25 (s, 1H), 7.64 (d, *J* = 8.4 Hz, 2H), 7.19 (d, *J* = 8.3 Hz, 2H), 3.82 (s, 3H), 2.74 (s, 3H), 2.35 (d, *J* = 3.7 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 161.92, 150.16, 148.10, 137.67, 130.42, 128.04, 126.91, 126.41, 124.58, 122.41, 121.33, 119.69, 17.76. HRMS *m/z* (ESI) [M + Na⁺]: 293.1260.

General Experimental Procedure B


Cu(OTf)₂ (3.6 mg, 0.01 mmol), *N,N*-bis(pyridin-2-ylmethyl)phenylamine (L_N) (4.1 mg, 0.015 mmol), Et₃N (0.1 mL), *N*-(pyridin-2-ylmethyl)aniline derivatives (0.1 mmol) were mixed in dried DMF (1 mL) in a 35 mL Teflon screwcap sealed tube. The tube was charged with O₂ (1 atm) and the mixture was vigorously stirred at RT for 24 h. After reaction was completed, the reaction mixture was diluted with dichloromethane (20 mL), filtered through a pad of silica gel and concentrated under reduced pressure. The crude product was purified on a silica gel column.

(22) *N*-(pyridin-2-ylmethylene)aniline (3a)⁵




Following the general experimental procedure B presented above, using *N*-(pyridin-2-ylmethyl)aniline (18.3 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a yellow oil (83% yield); ¹H NMR (400 MHz, CDCl₃): δ 8.85 – 8.60 (m, 2H), 8.22 (d, *J* = 7.7 Hz, 1H), 7.94 – 7.78 (m, 1H), 7.50 – 7.36 (m, 3H), 7.37 – 7.24 (m, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 160.65, 154.54, 150.96, 149.70, 136.74, 129.27, 126.78, 125.19, 121.93, 121.13. HRMS *m/z* (ESI) [*M* + H⁺]: 183.0917.

(23) 4-methyl-*N*-(pyridin-2-ylmethylene)aniline (3b)⁶




Following the general experimental procedure B presented above, using 4-methyl-*N*-(pyridin-2-ylmethyl)aniline (19.8mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a yellow oil (88% yield); H NMR (400 MHz, CDCl₃): δ 8.77 – 8.71 (m, 1H), 8.64 (s, 1H), 8.22 (d, *J* = 7.9 Hz, 1H), 7.89 – 7.80 (m, 1H), 7.38 (ddd, *J* = 7.5, 4.8, 1.2 Hz, 1H), 7.25 (s, 4H), 2.41 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.71, 154.72, 149.69, 148.33, 136.68, 129.88, 125.02, 121.83, 121.13, 115.27, 76.73, 21.09.

(24) thyl-*N*-(pyridin-2-ylmethylene)aniline (3c)⁷



Following the general experimental procedure B presented above, using 3-methyl-*N*-(pyridin-2-ylmethyl)aniline (19.8 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a yellow oil (60% yield); ¹H NMR (400 MHz, CDCl₃): δ 8.75 (d, *J* = 4.3 Hz, 1H), 8.62 (s, 1H), 8.21 (d, *J* = 7.9 Hz, 1H), 7.85 (td, *J* = 7.6, 1.4 Hz, 1H), 7.41 (ddd, *J* = 7.5, 4.9, 1.1 Hz, 1H), 7.33 (t, *J* = 7.6 Hz, 1H), 7.18 – 7.10 (m, 3H), 2.42 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 160.30, 149.71, 139.13, 137.10, 136.83, 129.08, 127.90, 127.62, 125.22, 122.02, 121.95, 118.09, 21.41.


(25) 2-methyl-*N*-(pyridin-2-ylmethylene)aniline (3d)⁸



Following the general experimental procedure B presented above, using 2-methyl-*N*-(pyridin-2-ylmethyl)aniline (19.8mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a yellow oil (28% yield); ¹H NMR (400 MHz, CDCl₃): δ 8.74 (d, *J* = 4.4 Hz, 1H), 8.54 (s, 1H), 8.29 (d, *J* = 7.9 Hz, 1H), 7.85 (td, *J* = 7.6,


1.3 Hz, 1H), 7.40 (ddt, $J = 7.7, 4.0, 2.0$ Hz, 1H), 7.23 – 7.17 (m, 1H), 6.79 – 6.69 (m, 3H), 2.42 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 159.91, 150.06, 149.60, 136.67, 132.27, 130.40, 127.89, 126.83, 126.40, 125.07, 121.67, 117.58, 17.87.

(26) 4-ethyl-N-(pyridin-2-ylmethylene)aniline (3e)⁹




Following the general experimental procedure B presented above, using *4-ethyl-N-(pyridin-2-ylmethyl)aniline* (21 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a yellow oil (74% yield); ^1H NMR (400 MHz, CDCl_3): δ 8.73 (ddd, $J = 4.8, 1.6, 0.9$ Hz, 1H), 8.65 (d, $J = 4.7$ Hz, 1H), 8.23 (d, $J = 7.9$ Hz, 1H), 7.83 (td, $J = 7.6, 1.4$ Hz, 1H), 7.38 (ddd, $J = 7.5, 4.9, 1.1$ Hz, 1H), 7.28 (s, 3H), 7.01 (d, $J = 8.4$ Hz, 1H), 6.69 – 6.63 (m, 1H), 2.71 (q, $J = 7.6$ Hz, 2H), 1.30 – 1.27 (m, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 159.72, 154.76, 149.68, 148.51, 143.18, 136.67, 128.68, 125.00, 121.83, 121.20, 115.29, 28.49, 15.59.

(27) N-((4-chloropyridin-2-yl)methylene)aniline (3f)



Following the general experimental procedure B presented above, using *N-((4-chloropyridin-2-yl)methyl)aniline* (22 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (10:1 v/v) to provide product as a yellow oil (82% yield); ^1H NMR (400 MHz, CDCl_3): δ 8.69 – 8.57 (m, 2H), 8.27 (d, $J = 1.7$ Hz, 1H), 7.50 – 7.37 (m, 3H), 7.33 (t, $J = 6.0$ Hz, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 159.19, 156.07, 150.46, 145.04, 129.33, 127.92, 127.18, 125.29, 122.05, 121.17. Anal. Calcd. (%) for $\text{C}_{12}\text{H}_9\text{N}_2\text{Cl}$: C, 66.52; H, 4.19; N, 12.93. Found (%) C, 66.13; H, 4.68; N, 12.55.

(28) 4-methoxy-N-(pyridin-2-ylmethylene)aniline⁶(3g)




Following the general experimental procedure B presented above, using *4-methoxy-N-(pyridin-2-ylmethyl)aniline* (22 mg, 0.1 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a yellow oil (51% yield); ^1H NMR (400 MHz, CDCl_3): δ 8.71 (ddd, $J = 4.8, 1.6, 0.9$ Hz, 1H), 8.64 (d, $J = 4.7$ Hz, 1H), 8.20 (dd, $J = 4.9, 4.0$ Hz, 1H), 7.85 – 7.77 (m, 1H), 7.39 – 7.32 (m, 3H), 7.00 – 6.94 (m, 2H), 3.85 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 158.96, 158.25, 154.86, 149.65, 143.69, 136.65, 124.84, 122.69, 121.67, 114.47, 55.50.

General Experimental Procedure C


To a solution of 2-clormethyl-pyridine hydrochloride (492 mg, 3 mmol) in H₂O (8 mL) was added aniline (3 mmol). The mixture was heated to 50°C and a solution of NaOH (240 mg, 6 mmol) in H₂O (2 mL) was quickly added. The dark brown mixture was stirred at 50°C for 24 h and the reacting solution was extracted with CHCl₃ (4×30 mL). The combined organic layer was dried over anhydrous Na₂SO₄ for 5 hours, filtered, and solvent was removed to give a brown oil. The crude product was purified on a silica gel column.

(29) N-(2-Pyridylmethyl)phenylamine¹⁰




Following the general experimental procedure C presented above, using aniline (280 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a brown solid (82% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.62 (d, *J* = 4.8 Hz, 1H), 7.65 (td, *J* = 7.7, 1.7 Hz, 1H), 7.36 (d, *J* = 7.8 Hz, 1H), 7.26 – 7.13 (m, 3H), 6.87 – 6.65 (m, 3H), 4.49 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 158.62, 149.22, 147.96, 136.70, 129.31, 122.14, 121.63, 117.60, 113.37, 113.08, 49.31, 29.77.

(30) 4-methyl-N-(pyridin-2-ylmethyl)aniline¹¹




Following the general experimental procedure C presented above, using *p*-Toluidine (321 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (3:1 v/v) to provide product as brown oil (76% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.61 (d, *J* = 4.7 Hz, 1H), 7.65 (t, *J* = 7.6 Hz, 1H), 7.36 (d, *J* = 7.8 Hz, 1H), 7.23 – 7.17 (m, 1H), 7.02 (d, *J* = 8.1 Hz, 2H), 6.62 (d, *J* = 8.2 Hz, 2H), 4.47 (s, 2H), 2.26 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 158.86, 149.22, 145.65, 136.65, 129.76, 126.81, 122.06, 121.61, 113.21, 60.43, 49.69, 20.42, 14.23.

(31) 3-methyl-N-(pyridin-2-ylmethyl)aniline¹²




Following the general experimental procedure C presented above, using *m*-Toluidine (321 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (3:1 v/v) to provide product as a brown oil (92% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.67 – 8.60 (m, 1H), 7.66 (td, *J* = 7.7, 1.8 Hz, 1H), 7.36 (d, *J* = 7.8 Hz, 1H), 7.20 (dd, *J* = 6.9, 5.2 Hz, 1H), 7.11 (t, *J* = 7.7 Hz, 1H), 6.63 – 6.49 (m, 3H), 4.49 (s, 2H), 2.31 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 158.71, 149.21, 147.98, 139.05, 136.65, 129.16, 122.08, 121.59, 118.58, 113.88, 110.21, 49.35, 21.67.

(32) 2-methyl-N-(pyridin-2-ylmethyl)aniline¹³




Following the general experimental procedure C presented above, using *o*-Toluidine (321 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a brown oil (82% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.70 – 8.56 (m, 1H), 7.67 (td, *J* = 7.7, 1.8 Hz, 1H), 7.37 (d, *J* = 7.8 Hz, 1H), 7.25 – 7.10 (m, 3H), 6.70 (ddd, *J* = 38.6, 22.6, 4.3 Hz, 2H), 4.55 (s, 2H), 2.30 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 158.58, 149.26, 145.90, 136.65, 130.12, 127.14, 122.35, 122.12, 121.61, 117.22, 110.14, 77.43, 77.11, 76.79, 49.29, 17.63.

(33) 2,6-dimethyl-N-(pyridin-2-ylmethyl)aniline¹⁴




Following the general experimental procedure C presented above, using 2,6-dimethylaniline (363 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a brown oil (61% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.64 (dd, *J* = 4.8, 0.6 Hz, 1H), 7.66 (td, *J* = 7.7, 1.8 Hz, 1H), 7.30 – 7.26 (m, 1H), 7.24 – 7.19 (m, 1H), 7.03 (d, *J* = 7.5 Hz, 2H), 6.86 (dd, *J* = 9.3, 5.6 Hz, 1H), 4.32 (s, 2H), 2.36 (s, 6H). ¹³C NMR (101 MHz, CDCl₃): δ 159.15, 149.29, 146.15, 136.47, 129.53, 128.82, 122.13, 122.02, 121.89, 53.68, 18.68.

(34) 4-ethyl-N-(pyridin-2-ylmethyl)aniline




Following the general experimental procedure C presented above, using 4-ethylaniline (366 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (6:1 v/v) to provide product as a colorless oil (81% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.62 (ddd, *J* = 4.9, 1.6, 0.8 Hz, 1H), 7.65 (td, *J* = 7.7, 1.8 Hz, 1H), 7.37 (d, *J* = 7.8 Hz, 1H), 7.20 (dd, *J* = 6.9, 5.4 Hz, 1H), 7.06 (t, *J* = 5.6 Hz, 2H), 6.72 – 6.60 (m, 2H), 4.48 (s, 2H), 2.58 (q, *J* = 7.6 Hz, 2H), 1.23 (t, *J* = 7.6 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 158.91, 149.22, 145.91, 136.65, 133.44, 128.60, 122.06, 121.62, 113.21, 49.70, 27.96, 15.97. Anal. Calcd. (%) for C₁₄H₁₆N₂: C, 79.21; H, 7.60; N, 14.01. Found (%) C, 79.02; H, 7.93; 14.57.

(35) 4-iodo-N-(pyridin-2-ylmethyl)aniline¹⁵




Following the general experimental procedure C presented above, using *p*-Iodoaniline (657 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (3:1 v/v) to provide product as a brown solid (77% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.59 (d, *J* = 4.4 Hz, 1H), 7.70 – 7.61 (m, 1H), 7.47 – 7.39 (m, 2H), 7.30 (d, *J* = 8.2 Hz, 1H), 7.20 (dd, *J* = 7.0, 5.1 Hz, 1H), 6.52 – 6.40 (m, 2H), 4.41 (s, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 157.77, 149.22, 147.45, 137.79, 136.76, 122.30, 121.63, 115.30, 78.22, 77.49, 77.17, 76.86, 48.91.

(36) 4-methoxy-N-(pyridin-2-ylmethyl)aniline¹²



Following the general experimental procedure B presented above, using p-Anisidine (370 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (65% yield). ^1H NMR (400 MHz, CDCl_3): δ 8.59 (d, $J = 4.8$ Hz, 1H), 7.64 (td, $J = 7.7, 1.0$ Hz, 1H), 7.40 – 7.32 (m, 1H), 7.22 – 7.15 (m, 1H), 6.86 – 6.76 (m, 2H), 6.71 – 6.59 (m, 2H), 4.43 (s, 2H), 3.75 (s, 3H). ^{13}C NMR (101 MHz, CDCl_3): δ 158.87, 152.22, 149.18, 142.16, 136.68, 122.09, 121.69, 114.89, 114.31, 55.77, 50.24.

(37) N-((4-chloropyridin-2-yl)methyl)aniline




Following the general experimental procedure B presented above, using 4-chloro-2-(chloromethyl)pyridine (594 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a yellow solid (62% yield). ^1H NMR (400 MHz, CDCl_3): δ 8.50 (d, $J = 5.3$ Hz, 1H), 7.41 (d, $J = 1.6$ Hz, 1H), 7.21 (tt, $J = 9.6, 1.9$ Hz, 3H), 6.83 – 6.60 (m, 3H), 4.48 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 160.78, 150.11, 147.54, 144.93, 129.35, 122.61, 121.83, 117.98, 113.06, 49.23. HRMS m/z (ESI) $[\text{M} + \text{H}^+]$: 219.0685.

General Experimental Procedure D


A mixture of 2-pyridinecarbaldehyde (300 mg, 0.3 mmol) and aniline (0.3 mmol) was heated to reflux in dry toluene for 3h. The solvent was removed under reduced pressure to afford the crude product, which was dissolved in $\text{CH}_3\text{OH}/\text{CH}_2\text{Cl}_2$ [2:8 (v/v), 10 mL] and the solution was cooled in an ice bath. NaBH_4 (52 mg, 1.39 mmol) was added in two batches between an interval of 30 mins. After the addition of NaBH_4 was completed, the mixture was stirred for an additional 2 h. The solution was then diluted with water (20 mL) and extracted with CH_2Cl_2 (3 \times 20 mL). The organic layers were combined and dried with anhydrous Na_2SO_4 . The solvent was removed under reduced pressure and the crude product was purified on a silica column.

(38) N-(pyridin-2-ylmethyl)-4-(trifluoromethyl)aniline¹⁶




Following the general experimental procedure D presented above, using 4-(Trifluoromethyl)aniline (483 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (74% yield). ^1H NMR (400 MHz, CDCl_3): δ 8.69 – 8.57 (m, 1H), 7.75 – 7.65 (m, 1H), 7.42 (t, $J = 9.4$ Hz, 2H), 7.32 (d, $J = 7.8$ Hz, 1H), 7.27 – 7.21 (m, 1H), 6.70 (d, $J = 8.5$ Hz, 2H), 5.44 – 5.17 (m, 1H), 4.50 (d, $J = 5.3$ Hz, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 157.24, 150.30, 149.26, 136.78, 126.64, 126.60, 123.66, 122.39, 121.62, 119.15, 118.83, 112.17, 48.53.

(39) phenyl(4-((pyridin-2-ylmethyl)amino)phenyl)methanone



Following the general experimental procedure D presented above, using (4-aminophenyl)-(phenyl)methanone (576 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (68% yield). ^1H NMR (400 MHz, CDCl_3) δ 8.61 – 8.49 (m, 1H), 7.63 (tt, $J = 12.3, 6.1$ Hz, 1H), 7.43 – 7.38 (m, 2H), 7.37 – 7.30 (m, 3H), 7.28 – 7.23 (m, 1H), 7.21 – 7.12 (m, 3H), 6.70 – 6.54 (m, 2H), 5.76 (s, 1H), 4.41 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 158.48, 149.14, 147.38, 144.43, 136.75, 133.32, 128.30, 127.99, 127.12, 126.40, 122.16, 121.63, 112.98, 77.42, 77.10, 76.78, 75.91, 49.21. HRMS m/z (ESI) $[\text{M} + \text{H}^+]$: 291.1492.

(40) N-benzyl-1-(pyridin-2-yl)methanamine




Following the general experimental procedure D presented above, using phenylmethanamine (321 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (1:3 v/v) to provide product as a yellow oil (90% yield). ^1H NMR (400 MHz, CDCl_3): δ 8.58 (d, $J = 4.3$ Hz, 1H), 7.67 (dtd, $J = 13.4, 7.7, 1.8$ Hz, 1H), 7.42 – 7.31 (m, 5H), 7.30 – 7.23 (m, 1H), 7.18 (dd, $J = 6.6, 5.0$ Hz, 1H), 3.95 (s, 2H), 3.87 (s, 2H). ^{13}C NMR (101 MHz, CDCl_3): δ 159.73, 149.32, 140.12, 136.47, 128.42, 128.28, 127.01, 122.39, 121.98, 54.51, 53.52.

General Experimental Procedure E


A mixture of 2-clormethyl-pridine hydrochloride derivatives (3 mmol), NaI (450 mg, 3 mmol), NaOH (240 mg, 6 mmol) and p-Toluidine (321 mg, 3 mmol) was heated to reflux in dry CH_3CN for 24h. After reaction was completed, the reaction mixture was diluted with dichloromethane (20 mL), filtered through a pad of silica gel and concentrated under reduced pressure. The crude product was purified on a silica gel column.

(41) 4-methyl-N-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)aniline




Following the general experimental procedure E presented above, using Aniline (280 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (54% yield). ^1H NMR (400 MHz, CDCl_3): δ 8.41 (d, $J = 5.7$ Hz, 1H), 7.06 (d, $J = 8.0$ Hz, 2H), 6.71 (ddd, $J = 14.4, 8.1, 4.1$ Hz, 3H), 4.43 (q, $J = 7.9$ Hz, 2H), 4.35 (s, 2H), 2.28 (d, $J = 7.2$ Hz, 6H). ^{13}C NMR (101 MHz, CDCl_3): δ 161.22, 156.81, 147.39, 145.90, 129.76, 126.49, 119.85, 113.23, 105.27, 65.55, 65.19, 46.76, 20.43, 9.52. HRMS m/z (ESI) $[\text{M} + \text{H}^+]$: 311.1367.

(42) N-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)-4-methylaniline




Following the general experimental procedure E presented above, using 2-(chloromethyl)-4-(3-methoxypropoxy)-3-methylpyridine hydrochloride (798 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (3:1 v/v) to provide product as a white solid (78% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.35 (d, *J* = 5.7 Hz, 1H), 7.04 (t, *J* = 13.7 Hz, 2H), 6.77 – 6.70 (m, 3H), 4.33 (s, 2H), 4.20 – 4.09 (m, 2H), 3.66 – 3.54 (m, 2H), 3.39 (s, 3H), 2.28 (d, *J* = 7.6 Hz, 3H), 2.22 (s, 3H), 2.13 (dd, *J* = 12.3, 6.1 Hz, 2H). ¹³C NMR (101 MHz, CDCl₃): δ 162.94, 155.64, 147.29, 146.11, 129.71, 126.23, 119.20, 113.20, 105.47, 68.95, 64.95, 58.80, 46.76, 29.42, 20.45, 9.64. HRMS *m/z* (ESI) [*M* + *H*⁺]: 301.1911.

(43) N-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-4-methylaniline




Following the general experimental procedure E presented above, using 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine hydrochloride (666 mg, 3 mmol) as substrates instead, purified by column eluted with petroleum ether/EtOAc (3:1 v/v) to provide product as a white solid (72% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.25 (d, *J* = 5.6 Hz, 1H), 7.03 (d, *J* = 8.0 Hz, 2H), 6.83 (t, *J* = 8.5 Hz, 1H), 6.73 (d, *J* = 8.3 Hz, 2H), 4.43 (s, 2H), 3.94 (t, *J* = 10.1 Hz, 6H), 2.24 (d, *J* = 16.0 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 158.30, 151.61, 146.00, 145.32, 142.89, 129.67, 126.50, 113.48, 106.75, 60.83, 55.68, 44.16, 20.42. HRMS *m/z* (ESI) [*M* + *H*⁺]: 257.1648.

(44) N-benzyl-N-(pyridin-2-ylmethyl)aniline¹⁷



To a solution of 2-chloromethyl-pyridine hydrochloride (984 mg, 6 mmol) in H₂O (10 mL) was added aniline (3 mmol). The mixture was heated to 50°C and an aqueous solution (2 mL) of NaOH (360 mg, 9 mmol) was quickly added. The dark brown mixture was stirred at 50°C for 24 h and the resultant solution was extracted with CHCl₃ (4×30 mL). The combined organic layers were combined and dried over anhydrous Na₂SO₄ for 10 hours, filtered, and the solvent was removed to give a brown oil. The crude product was purified on a silica column eluted with petroleum ether/EtOAc (1:2 v/v) to provide product as a white solid (80% yield). ¹H NMR (400 MHz, CDCl₃): δ 8.67 – 8.57 (m, 2H), 7.64 (td, *J* = 7.7, 1.8 Hz, 2H), 7.29 (d, *J* = 7.0 Hz, 2H), 7.22 – 7.14 (m, 4H), 6.74 (td, *J* = 8.3, 4.6 Hz, 3H), 4.85 (s, 4H). ¹³C NMR (101 MHz, CDCl₃): δ 158.85, 149.73, 148.20, 136.85, 129.31, 122.04, 120.81, 117.22, 112.51, 57.30.

(45) N-methyl-N-(pyridin-2-ylmethyl)aniline¹⁸



To a mixture of *N*-(pyridin-2-ylmethyl)aniline (550 mg, 0.3 mmol), 40% formaldehyde (3.75 g, 50




mmol) and ethylic acid (4.5 mL) was added CH₃CN (15 mL). The mixture was vigorously stirred at RT for 24 h. NaBH₄ (52 mg, 1.39 mmol) was added in two batches between an interval of 30 mins in an ice bath. After the addition of NaBH₄ was completed, the mixture was stirred for an additional 2 h and at RT for 24 h. The solution was then diluted with water (20 mL) and extracted with CH₂Cl₂ (3×20 mL). The organic layer was combined and dried with anhydrous Na₂SO₄. Solvent was removed under reduced pressure, and the crude product was purified by on a silica column eluted with petroleum ether/EtOAc (5:1 v/v) to provide product as a white solid (66% yield). ¹H NMR (400 MHz, CDCl₃) δ 8.61 (dd, *J* = 4.1, 0.8 Hz, 1H), 7.62 (td, *J* = 7.7, 1.8 Hz, 1H), 7.28 – 7.16 (m, 4H), 6.83 – 6.71 (m, 3H), 4.68 (s, 2H), 3.14 (s, 3H). ¹³C NMR (101 MHz, CDCl₃): δ 159.42, 149.56, 149.25, 136.77, 129.24, 121.92, 120.76, 116.71, 112.21, 58.88, 39.09. Anal. Calcd. (%) for C₂₈H₃₀CuF₆N₆O₆S₂: C, 42.66; H, 3.84; N, 10.66. Found (%) C, 43.23; H, 3.21; 10.12.

References



- 1, Q. Li, S-Y. Zhang, G. He, Z. Ai, W. A. Nack, and G. Chen. *Org. Lett.*, **2014**, *16*, 1764–1767.
- 2, S. Cai, C. Chen, P. Shao, and C. Xi. *Org. Lett.*, **2014**, *16*, 3142–3145.
- 3, Á. M. Martínez, N. Rodríguez, R. G. Arrayás and J. C. Carretero. *Chem. Commun.*, **2014**, *50*, 2801-2803.
- 4, T. T. Dang, Y. Zhu, J. S. Y. Ngiam, S. C. Ghosh, A. Chen, and A. M. Seayad, *ACS Catal.*, **2013**, *3*, 1406–1410.
- 5, M. C. Law, T. W. Cheung, K.-Y. Wong, and T. H. Chan, *J. Org. Chem.*, **2007**, *72*, 923–929.
- 6, K. Sreenath, Z. Yuan, M. Macias-Contreras, V. Ramachandran, R. J. Clark, and L. Zhu, *Eur. J. Inorg. Chem.* **2016**, 3728.
- 7, Y. Zhou, L. Li, H. Ye, L. Zhang, and L. You, *J. Am. Chem. Soc.*, **2016**, *138*, 381–389.
- 8, Y. Chai, S. Shen, G. Weng and Y. Pan, *Chem. Commun.*, **2014**, *50*, 11668-11671.
- 9, P. Harding, D. J. Harding , N. Soponrat , K. Tinpun , S.Samuadnuan and H. Adams, *Aust. J. Chem.*, **2010**, *63*, 75- 82.
- 10, Y. Chai, S. Shen, G. Weng and Y. Pan. *Chem. Commun.*, 2014, *50*, 11668-11671.
- 11, M. Mastalir, G. Tomsu, E. Pittenauer, G. Allmaier, and K. Kirchner. *Org. Lett.*, **2016**, *18*, 3462–3465.
- 12, S. S. Kampmann, B. W. Skelton, D. A. Wild, G. A. Koutsantonis, and S. G. Stewart. *Eur. J. Org. Chem.*, **2015**, *27*, 5995 – 6004.
- 13, H.-M. Li, C. Xu, Z.-Q. Wang and W.-J. Fu, *Bull. Korean Chem.Soc*, **2015**, *36*, 2557-2560.
- 14, Y.-C. Lin, K.-H. Yu, S.-L. Huang, Y-H. Liu, Y. Wang, S.-T. Liu and J. T. Chen. *Dalton Trans.*, **2009**, *41*, 9058-9067.
- 15, V. V. Kouznetsov, L. Y. V. Me´ndez, M. Sortino, Y. Va´squez, M. P. Gupta, M. Freile, R. D. Enrize and S. A. Zacchino, *Bioorg. Med. Chem.*, **2008**, *16*, 794-809.
- 16, H.-R. Pan, Y-J. Li, C-X. Yan, J. Xing, and Y. Cheng. *J. Org. Chem.*, **2010**, *75*, 6644–6652.
- 17, X. Peng, J. Du, J. Fan, J. Wang, Y. Wu, J. Zhao, S. Sun and T. Xu, *J. Am. Chem. Soc.*, **2007**, *129*, 1500–1501.
- 18, Y. Gui, L.-L. Liao, L. Sun, Z. Zhang, J.-H. Ye, G. Shen, Z.-P. Lu, W.-J. Zhou and D.-G. Yu, *Chem. Commun.*, **2017**, *53*, 1192-1195.

NMR and Mass spectra



N-phenylpicolinamide





N-(p-tolyl)picolinamide





N-(m-tolyl)picolinamide






N-(o-tolyl)picolinamide





N-(2,6-dimethylphenyl)picolinamide





N-(4-ethylphenyl)picolinamide





N-(4-methoxyphenyl)picolinamide






N-(4-iodophenyl)picolinamide





N-(4-(trifluoromethyl)phenyl)picolinamide






N-(4-benzoylphenyl)picolinamide






11, 4-chloro-N-phenylpicolinamide






4-(3-methoxypropoxy)-3-methyl-N-(p-tolyl)picolinamide






3-methyl-N-(p-tolyl)-4-(2,2,2-trifluoroethoxy)picolinamide





4-methoxy-3,5-dimethyl-N-(p-tolyl)picolinamide





N-(pyridin-2-ylmethylene)aniline





4-methyl-N-(pyridin-2-ylmethylene)aniline





3-methyl-N-(pyridin-2-ylmethylene)aniline





4-ethyl-N-(pyridin-2-ylmethylene)aniline





N-((4-chloropyridin-2-yl)methylene)aniline





4-methoxy-N-(pyridin-2-ylmethylene)aniline





N-(pyridin-2-ylmethyl) aniline





4-methyl-N-(pyridin-2-ylmethyl)aniline





3-methyl-N-(pyridin-2-ylmethyl)aniline





2-methyl-N-(pyridin-2-ylmethyl)aniline





2,6-dimethyl-N-(pyridin-2-ylmethyl)aniline





4-ethyl-N-(pyridin-2-ylmethyl)aniline






4-iodo-N-(pyridin-2-ylmethyl)aniline





4-methoxy-N-(pyridin-2-ylmethyl)aniline






N-((4-chloropyridin-2-yl)methyl)aniline





N-(pyridin-2-ylmethyl)-4-(trifluoromethyl)aniline






phenyl(4-((pyridin-2-ylmethyl)amino)phenyl)methanone






N-benzyl-1-(pyridin-2-yl)methanamine






1, 4-methyl-N-((3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)aniline





N-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)-4-methylaniline



N-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-4-methylaniline



N-benzyl-N-(pyridin-2-ylmethyl)aniline



N-methyl-N-(pyridin-2-ylmethyl)aniline

